Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kayla Johnson

Nurse Practitioner, Family Conway, AR Nurse Practitioner

NPI 1255839858 CMS profile 10863370

655 Dave Ward Dr, Conway, AR 72034

Open in the dashboard

General payments

$8,935

505 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kayla Johnson of Conway, AR is reported in the CMS Open Payments database as having received $8,935 across 505 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,800 91
2024 General $2,041 113
2023 General $1,912 107
2022 General $2,270 135
2021 General $912 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kayla Johnson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kayla Johnson were reported at $1,800. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kayla Johnson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $912 $124 $35–$379 $132
2022 $2,270 $141 $44–$430 $149
2023 $1,912 $154 $49–$476 $160
2024 $2,041 $165 $51–$504 $164
2025 $1,800 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,847 103 payments
  2. AbbVie, Inc. $1,705 105 payments
  3. UCB, Inc. $1,516 69 payments
  4. Pfizer Inc. $828 66 payments
  5. Mallinckrodt Hospital Products Inc. $632 28 payments
  6. E.R. Squibb & Sons, L.L.C. $470 22 payments
  7. Janssen Biotech, Inc. $355 21 payments
  8. GlaxoSmithKline, LLC. $317 20 payments
  9. AstraZeneca Pharmaceuticals LP $214 13 payments
  10. Lilly USA, LLC $197 12 payments
  11. Other $854 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,875 504 payments
  2. Education $60 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,145 68 payments
  2. Cimzia $1,079 48 payments
  3. Otezla $855 45 payments
  4. XELJANZ $778 61 payments
  5. ACTHAR $632 28 payments
  6. Enbrel Inflammation $598 32 payments
  7. Enbrel Inflammation $552 27 payments
  8. ORENCIA $470 22 payments
  9. Bimzelx $425 20 payments
  10. SKYRIZI $333 20 payments
  11. Other $3,971 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

4,379

Median for Nurse Practitioner: 389

Drug cost

$84,074

Median for Nurse Practitioner: $21,885

Branded share of claims

13.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 737 $27,151
Duloxetine Hcl Generic 872 $13,457
Azathioprine Generic 207 $6,914
Methotrexate Methotrexate Sodium Brand 444 $6,758
Pregabalin Generic 207 $6,617
Gabapentin Generic 433 $6,063
Mycophenolate Mofetil Generic 17 $1,811
Sulfasalazine Generic 97 $1,794
Naproxen Generic 99 $1,608
Prednisone Generic 231 $1,339

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$140,756

Of which drugs: $118,409

Medicare patients

159

Average age 71

Services billed

4,804

121 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 49%
Chronic kidney disease 35%
Depression 33%
Ischemic heart disease 31%
Diabetes 26%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 25 64 $32
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 346 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $289
$289 — —
Cimzia
  • UCB, Inc. $277
$277 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $173
$173 — —
XELJANZ
  • PFIZER INC. $170
$170 — —
Enbrel
  • Amgen Inc. $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record